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Objectives: Polypharmacy and multimorbidity are
common in long-term care facilities (LTCFs). Reducing
polypharmacy may reduce adverse events and maintain
quality of life. Deprescribing refers to reducing
medications after consideration of therapeutic goals,
benefits and risks, and medical ethics. The objective
was to use nominal group technique (NGT) to generate
then rank factors that general medical practitioners
(GPs), nurses, pharmacists and residents or their
representatives perceive are most important when
deciding whether or not to deprescribe medications.
Design: Qualitative research using NGT.
Setting: Participants were invited if they worked with,
or resided in LTCFs across metropolitan and regional
South Australia.
Participants: 11 residents/representatives, 19 GPs,
12 nurses and 14 pharmacists participated across six
separate groups.
Methods: Individual groups of GPs, nurses,
pharmacists and residents/representatives were
convened. Using NGT each group ranked factors
perceived to be most important when deciding whether
or not to deprescribe. Then, using NGT, the prioritised
factors from individual groups were discussed and
prioritised by a multidisciplinary metropolitan and
regional group comprised of resident representatives,
GPs, nurses and pharmacists.
Results: No two groups had the same priorities. GPs
ranked ‘evidence for deprescribing’ and
‘communication with family/resident’ as most important
factors. Nurses ranked ‘GP receptivity to deprescribing’
and ‘nurses ability to advocate for residents’ as most
important. Pharmacists ranked ‘clinical appropriateness
of therapy’ and ‘identifying residents’ goals of care’ as
most important. Residents ranked ‘wellbeing of the
resident’ and ‘continuity of nursing staff’ as most
important. The multidisciplinary groups ranked
‘adequacy of medical and medication history’ and
‘identifying residents’ goals of care’ as most important.
Conclusions: While each group prioritised different
factors, common and contrasting factors emerged.
Future deprescribing interventions need to consider the
similarities and differences within the range of factors
prioritised by residents and health professionals.
INTRODUCTION
Older people living in long-term care facilities
(LTCFs) often have multimorbidity.1 Between
38% and 91% of residents take ≥5 medica-
tions.2 As people age the beneﬁt-to-risk ratio
of medications may change, and this may
mean that medications that were once pre-
scribed appropriately become inappropriate.3
Polypharmacy in older people is associated
with hospitalisations, adverse drug events
(ADEs), drug–drug interactions, drug–
disease interactions, falls, impaired functional
capacity and cognitive impairment.4–7
Deprescribing refers to the stepwise reduc-
tion of unnecessary or potentially inappropri-
ate medications (PIMs) after consideration
of therapeutic goals, beneﬁts and risks, and
medical ethics.8–11 One goal of deprescribing
is to reduce the negative outcomes associated
Strengths and limitations of this study
▪ This is which first study to consider which
factors are important for deprescribing from the
perspectives of general practitioners, nurses,
pharmacists, and residents and their
representatives.
▪ Participants were drawn for a large geographical
area to provide maximum variation of opinions
and experiences.
▪ A structured evaluative methodology was used
allowing groups to generate and prioritise factors
important for deprescribing.
▪ A limitation was that the results may not be gen-
eralisable to other countries where aged care
services are structured differently. Recruitment
by invitation may make the sample biased
towards motivated and enthusiastic participants
with an interest in deprescribing. This was a
strength because it enables a rich discussion of
factors important for deprescribing. However, it
is unclear whether less motivated participants
perceive similar factors as important.
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with polypharmacy.12 Preliminary research in older
people suggests that many medications can be with-
drawn safely, resulting in global improvements in patient
perceived health, reduced hospitalisations and increased
longevity.13 14 Despite this, over 50% of LTCF residents
take PIMs.15 16
Previous research has focused on family physician/
general medical practitioner (GP) perspectives on
deprescribing for community-dwelling patients,17 and
residents of LTCFs.18 19 Prescribers barriers to depre-
scribing include lack of awareness of the need to depre-
scribe, prescribing inertia, self-efﬁcacy and limited
feasibility due to external factors.20 Patients’ barriers to
deprescribing include lack of an established process,
uncertainty regarding the appropriateness, and fear of
medication cessation. Families have been identiﬁed as
possible barriers or enablers to deprescribing, while
patient ‘dislike’ of medications has been considered an
enabler.21
Prescribing decisions made by GPs may be inﬂuenced
by nurses, pharmacists, other medical specialists and
residents or their representatives.22 Each stakeholder
may perceive different factors to be important when
deciding whether deprescribing is warranted.
Furthermore, organisational culture within LTCFs can
inﬂuence medication use.23 Successful deprescribing is
likely to be dependent on agreed priorities that consider
the perspectives of multiple disciplines and the resi-
dent.24 25 Studies to date have focused on single groups
such as GPs or community-dwelling patients,25 26
whereas no studies have investigated the factors import-
ant to multiple disciplines and residents when consider-
ing deprescribing in LTCFs, either as individual groups,
or in a multidisciplinary setting.
Nominal group technique (NGT) and the Delphi
technique are the two most frequently used methods for
arriving at a group consensus.27–29 NGT is a structured
evaluative methodology used to generate and prioritise
ideas.28 30–32 NGT encourages a wider generation of
ideas than conventional discussion groups,31 and facili-
tates inclusion of all participants.30
AIM
The aim of the study was to rank factors that GPs,
nurses, pharmacists and residents perceive as most




NGT has been employed to analyse healthcare pro-
blems,33 in guideline development34 and to identify pri-
orities in primary care.32 35–37 The NGT was chosen over
Delphi technique as NGT involves participants in gener-
ating their own ideas, while also allowing participants to
hear and understand the perspectives of the collective
group. The use of a facilitator to moderate group
dynamics, as well as the use of anonymous ranking,
ensures no one individual is able to dominate the
group’s outcome.30
This study employed two phases (ﬁgure 1). In phase
1, the factors most important for deprescribing accord-
ing to individual groups of health professionals and resi-
dents and their representatives were generated. Phase 2
utilised. Mixed groups comprising of healthcare profes-
sionals and residents representatives.
The factors most important for deprescribing accord-
ing to individual groups of GPs, nurses, pharmacists and
residents and or their representatives were generated in
phase 1. We hypothesised that groups including resi-
dents’ representatives, GPs, nurses and pharmacists
(multidisciplinary groups) may identify different prior-
ities. Therefore, phase 2 involved two multidisciplinary
NGT groups comprising 2–3 residents’ representatives,
GPs, nurses and pharmacists. These groups discussed
the prioritised factors from phase 1 to generate a multi-
disciplinary ranked list of important factors considered
when deprescribing in LTCFs. One multidisciplinary
group was convened in a metropolitan area and the
other in a regional area. An independent experienced
facilitator was present for all sessions. Each NGT session
produced a prioritised list of important factors when
considering deprescribing in LTCFs.
Study setting and participants
NGT sessions were conducted with groups of health
professionals, permanent residents of LTCFs, as well as
residents’ representatives. Residents’ representatives
were invited to ensure the views of residents with cogni-
tive impairment were included. To ensure the
maximum variation of opinions and experiences, parti-
cipants were recruited and speciﬁcally selected from
across a large geographical area of South Australia
including the city of Adelaide, and the Fleurieu penin-
sular regional area. Furthermore, participants were
recruited to provide a broad range of ages, and length
of contact with LTCFs. To reduce potential reluctance
to voice opinions in front of work colleagues or care-
givers, groups were formulated to include participants
from a variety of workplaces including different GP
family practices, LTCFs, community pharmacies and
independent consultant pharmacists.29 Groups were
designed with approximately 10 participants to maintain
group dynamics.28 GPs who routinely care for residents
in LTCFs were invited to participate. Specialist geriatri-
cians were not invited to participate because GPs, rather
than geriatricians, are responsible for the majority of
prescribing within Australian LTCFs. Pharmacists who
supply medications to and/or have accreditation to
provide LTCF medication reviews were also invited to
participate. GP and pharmacist potential participants
were identiﬁed by external independent health profes-
sional support organisations. These organisations
included GP and pharmacist professional organisations
along with government-funded regional organisations
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responsible for the provision of professional develop-
ment and education to health professionals. To provide
a range of experience and training levels potential
nurse participants were purposefully selected from
various LTCFs by an organisation that provides aged
care services. The organisations also conducted pur-
poseful recruitment of residents such that the diversity
of the group was maximised according to comorbidities,
functional status, cognitive status and length of time in
LTCFs. Purposeful recruitment also allowed residents
representatives to be present on behalf of residents with
cognitive decline including dementia or Alzheimer’s
disease. Residents who had difﬁculty reading or writing
were provided with assistance during the NGT session.
To maximise variation of opinions and experiences, par-
ticipants from phase 1 were not included in phase
2. Phase 1 sessions involving GPs and pharmacists,
along with both phase 2 NGT sessions were held after
business hours in an independent location to allow
healthcare professionals to attend after work.
Data collection
Demographic data were collected from all participants
including age group. Residents recorded the number of
years they had lived in a LTCF, while health profes-
sionals recorded the number of years since initial
registration.
Measurements and definitions
Prior to each NGT, all participants were provided with
the same background reading to introduce the concept
of deprescribing. Each NGT session was conducted in
the same format. This involved an introduction, silent
individual generation of factors, discussion, generation
of themes and ranking of factors (ﬁgure 2).29 30 32 33 A
facilitator provided the introduction, reﬂecting what is
known from the literature from non-LTCF settings,
before asking each NGT group to broadly consider
‘What are the important factors that inﬂuence your deci-
sion whether or not to reduce medications for residents
of long term care facilities?’ (step 1). For phase 1, parti-
cipants were given 10 min silent time to write down all
factors they thought were important (step 2). During
step 3, the facilitator recorded all ideas on the board
until saturation of ideas was reached, before facilitating
discussion. Subsequent to the discussion, common
themes were generated. Participants then individually
and privately selected ﬁve factors from the newly gener-
ated themes they considered most important and
ranked them in priority order from 5 to 1 (step 5). Each
participant’s points were summed to determine the
factors overall rankings, which was then presented to the
group (step 6). Brief discussion was led by the facilitator
to conﬁrm the prioritised list was an accurate reﬂection
of the group’s collective priorities.
In phase 2 after the introduction, participants were
provided with the ‘top 5’ factors from the residents
group and each of the discipline-speciﬁc groups gener-
ated in phase 1. Participants silently considered these
for 10 min (step 2), before being led in a discussion by
the facilitator (step 3). Participants were asked to indi-
vidually and privately rank factors they perceived to be
most important as in phase 1 (step 5). The results were
reviewed by the group (step 6). To ensure participants
viewed the ‘top 5’ factors without bias, they were pre-
sented in alphabetical order without stating which spe-
ciﬁc group they originated from.
Ethical considerations
This study was approved by the Monash University
Human Research Ethics Committee. Participants pro-
vided written informed consent to participate and were
given an honorarium for their involvement.
Figure 1 Flow diagram for phase 1 and phase 2. GP, general medical practitioner.
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RESULTS
There were 56 participants across phase 1 and phase 2,
with demographic data presented in table 1.
Phase 1
High agreement existed within the individual groups,
with the ‘top 5’ factors accounting for 59–68% of the
groups’ prioritised vote (GPs 59%, nurses 65%, pharma-
cists 68% and residents 67%) (table 2). GPs ranked lack
of ‘evidence for deprescribing’ as the most important
factor and ‘ability to communicate the need to depre-
scribe to residents and their family’ as second most
important. Nurses ranked ‘GP receptivity to deprescrib-
ing’ and their ability to ‘advocate for the resident’ as the
Figure 2 Process of nominal
group technique (NGT).
Table 1 Demographics of nominal group participants




Residents/representatives 6 3:3 80–89 (70–79 to 90+) 3.0 (1–14)
GPs 13 9:4 50–59 (20–29 to 60–69) 27.0 (5–44)
Nurses 6 2:4 30–39 (20–29 to 60–69) 9.0 (1–30)
Pharmacists 9 5:4 40–49 (30–39 to 60–69) 23.0 (8–42)
Phase 2
Residents/representatives 5 1:4 60–69 (40–49 to 60–69) No answers given
GPs 6 2:4 40–49 (30–39 to 60–69) 15.5 (8–28)
Nurses 6 0:6 50–59 (20–29 to 60–69) 23.5 (3–39)
Pharmacists 5 2:3 50–59 (30–39 to 60–69) 28 (13–33)
Overall
Residents/representatives 11 4:7 70–79 (40–49 to 90+) 3.0 (1–14)
GPs 19 11:8 50–59 (20–29 to 60–69) 26.5 (5–39)
Nurses 12 2:10 50–59 (20–29 to 60–69) 13.5 (1–39)
Pharmacists 14 7:7 50–59 (30–39 to 60–69) 28.0 (8–42)
Years of experience=number of years since initial registration as a health professional, or the number of years residents had been living in
a LTCF.
GPs, general medical practitioners; LTCFs, long-term care facilities.
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ﬁrst and second most important factors. Pharmacists
ranked ‘clinical appropriateness of the prescribed
therapy’ and ‘difﬁculty in determining the residents’
goals of care’ as the ﬁrst and second most important
factors. Clinical appropriateness was perceived to
include the dose, duration of therapy, class of medica-
tion, presence of a suspected or actual ADEs, presence
of renal or hepatic impairment and the residents’ age
and life expectancy. Residents ranked ‘wellbeing of the
resident’ as the most important factor. Residents used
this broad heading to include their right to question
GPs about medications, to continue medications they
believed made them feel well, and cease the medications
they perceived contributed to ‘burden of medication
administration’ or caused ADEs. Residents ranked ‘con-
tinuity of nursing staff’ as the second most important
factor.
Phase 2
The ‘top 5’ factors identiﬁed by participants in phase 2
accounted for 52% of the metropolitan, and 65% of the
rural groups’ prioritised vote (table 2). The regional
group prioritised a narrow selection of factors, with 7 of
the 21 factors presented to them not receiving any votes.
The metropolitan group prioritised a wider selection of
factors, with ﬁve factors not receiving any votes. The
regional group ranked the ‘residents’ goals of care’ the
highest, while the metropolitan group ranked ‘adequacy
of medical and medication history’ the highest.
DISCUSSION
This was the ﬁrst study to rank factors important for
deprescribing in LTCFs from the perspectives of health
professionals and residents. Previous research has only
investigated factors from the perspective of GPs and
patients, with a recent review highlighting barriers to
deprescribing in various settings.11 18 19 26 However,
there is a dearth of research investigating barriers to
deprescribing from the perspectives of nurses, pharma-
cists or residents. Although common factors were identi-
ﬁed, each NGT group had different priorities. This
suggests that successful deprescribing interventions need
to recognise and address a range of factors important to
residents and health professionals.
Communication was an important similar theme iden-
tiﬁed by each group. Residents perceived good communi-
cation with health professionals is required to achieve
‘wellbeing of the resident’. The second highest ranked
factor by residents, ‘continuity of nursing staff’, also
related to communication with known and trusted health
professionals. Residents commented that unfamiliar
nurses were unlikely to be aware of their medical, social
and medication history and preferences. This was per-
ceived to potentially result in residents’ voices not being
heard, which was a barrier to deprescribing. Nurses
ranked ‘GP receptivity’ as their top factor. They identiﬁed
communicating with GPs, other nurses and the residents’
Table 2 Top seven factors generated per group
Group Ranking
Residents
Well-being of the resident 1
Continuity of nursing staff 2
Feeling of wellness due to medication 3
Burden of medication administration 4
Residents have the right to question their GP 4
Voice of the resident is not heard 6
Respect the GP and do as I am told 6
GPs
Evidence for deprescribing 1
Communication with resident/family 2
GP funding 3
Health system structure 3
Adequacy of medical and medication history 5
Fear of deterioration 5
Residents willingness to deprescribe 7
Nurses
GP receptivity 1
Nurses ability to advocate for residents 2
Regular review of medical conditions 3
Understanding of medications by nurse,
family and resident
4
Nurses understanding of the residents
medical conditions
5
Family—support, beliefs and conflicts 6
Communication between nurses 6
Health literacy of resident and family 6
Pharmacists
Clinical appropriateness of prescribed therapy 1
Resident’s goals of care 2
Opportunity and funding for pharmacist
follow-up monitoring
3
Resident’s frailty status and other medical
conditions
4
Presence of ADEs 4
Attitudes of prescribers 6
Burden of medication administration 7
Multidisciplinary—regional
Resident’s goals of care 1
Well-being of the resident 2
Health system structure 3
Clinical appropriateness of prescribed
therapy
4
Evidence for deprescribing 5
Resident’s frailty status and other medical
conditions
5
Regular review of medical conditions 7
Multidisciplinary—metropolitan
Adequacy of medical and medication history 1
Health system structure 2
Evidence for deprescribing 3
Communication with resident/family 4
GP receptivity 5
Continuity of nursing staff 6
Resident’s goals of care 6
Understanding of medications by nurse,
family and resident
6
Some factors received equal scores and are therefore ranked the
same importance.
ADEs, adverse drug events; GP, general medical practitioner.
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family can be difﬁcult. Nurses may have an important
role in identifying medications appropriate for depre-
scribing.38 However, in Australia GPs are primarily
responsible for care of residents in LTCFs and therefore
responsible for altering medication charts. Nurses com-
mented that the success of their recommendations to
deprescribe relied on communication with, and receptiv-
ity of the GP. While recent research in LTCFs highlights
the important role of nurses and organisational culture
in prescribing decisions,38 our results reveal nurses feel
that potentially this important role may be dismissed or
not taken seriously.
GPs ranked difﬁculty communicating the need to
deprescribe to residents and families as the second most
important factor. They identiﬁed a need for guidelines
to standardise the process of deprescribing, along with a
structured dialogue, to facilitate communicating the
beneﬁts of deprescribing with residents and their fam-
ilies. This was consistent with recent Canadian and
Dutch research that reported that elucidating patients’
preferences and treatment goals was a barrier to depre-
scribing.25 39 Furthermore, GPs reported complexities
communicating with specialist physicians. GPs discussed
being intimidated by specialist physicians for deprescrib-
ing medications they initiated, with one recounting
being ‘scorned by a colleague’. Furthermore, GPs
expressed disappointment when deprescribed medica-
tions were restarted by a specialist physician or in hos-
pital. These factors have also been identiﬁed in previous
research.19 25 40 41 Likewise, pharmacists recognised
these factors as important, with communication under-
pinning their top two factors.
Similar to the individual groups, factors relating to
communication were prioritised by both multidisciplin-
ary groups. However, differences existed between metro-
politan and regional views. The metropolitan group
prioritised ‘adequacy of medical and medication
history’. This may reﬂect residents consulting new
health professionals following admission to a LTCF, high-
lighting inadequate communication between various
health professions and residents or their representatives.
In contrast, the regional group prioritised the ‘residents’
goals of care’ as most important. It was noted that when
residents and GPs had long-established relationships it
was challenging to discuss the shift from preventative
care to palliative care. This is consistent with previous
research.25
Reluctance to deprescribe due to ‘fear of deterior-
ation’ was highly ranked by GPs, and discussed by the
pharmacist, resident and multidisciplinary groups. This
was consistent with the attitude to deprescribing
described by Harriman et al19 ‘if it ain’t broke, don’t ﬁx
it’. This concern may be mitigated by gradual individual
medication withdrawal, allowing restart if the condition/
symptoms return.21 This requires careful ongoing moni-
toring and good communication. However, all groups
raised lack of ‘continuity of nursing staff’ as a potential
barrier to deprescribing. GPs perceived poor continuity
of nurse staff limited the opportunity for appropriate
monitoring after deprescribing, which may lead to
restarting deprescribed medications. Pharmacists per-
ceived lack of ‘continuity of nursing staff’ limited their
ability to determine residents’ goals of care. Continuity
of nursing staff, or ‘consistent assignment,’ may improve
residents’ quality of life, although the evidence is incon-
sistent.42–45
The ‘evidence for deprescribing’ was the highest
ranked factor by the GP group and was prioritised by
both multidisciplinary groups. Some participants were
either unaware of the evidence or unsure how to apply
the results of deprescribing trials to their clinical prac-
tice.13 14 38 46–50 The lack of evidence was discussed not
only in terms of deprescribing but also initiation and
continuation of medications in frail older people. Older
people are often excluded from clinical trials and clin-
ical practice guidelines may not make recommendations
speciﬁc to people who are frail or have multimorbidity.
A systematic review found 81.3% of randomised con-
trolled trials excluded patients on the basis of
comorbidities, and 38.5% excluded patients aged
>65 years.51
The factor ‘burden of medication administration’ was
prioritised by the resident group and was similarly dis-
cussed by the nurse and pharmacist groups. This
included difﬁculties swallowing large tablets, taste of
crushed medications, and use of devices such as inha-
lers, injections and eye drops. Residents, nurses and
pharmacists considered that having a high medication
burden was a facilitator of deprescribing.
All groups discussed health system structure concerns
including limited funding and incomplete medical and
medication histories. Medication histories rarely detail
why and when medications were initiated and which pre-
scriber is responsible for ongoing monitoring. All
groups agreed that monitoring residents following
deprescribing was essential. However, the current health
system structure was perceived as not supporting
ongoing monitoring.
The ‘top-5’ highest ranked outcomes from both
multidisciplinary groups included ‘top 5’ factors from
most of the individual groups, with each group being
represented within the ‘top 7.’ The multidisciplinary
group discussions allowed participants’ to consider
other points of view, with the ﬁnal ranking reﬂecting
this discussion. This was most evident with the factor
‘evidence for deprescribing’ which was ranked highest
by the GP group, but was not ranked by the other indi-
vidual groups. After discussion by residents’ represen-
tatives, GPs, nurses and pharmacists, it ranked in the
‘top 5’ for both multidisciplinary groups. Previous
research has demonstrated that high-quality multidis-
ciplinary teamwork improves prescribing in
LTCFs.24 52–54 Our results suggest for deprescribing to
be effective it is essential to take into consideration
the views of residents and individual health
professionals.
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Implications for practice
The results of this study should be considered when
instigating interventions to deprescribe in LTCFs. This
study highlighted participants uncertainty regarding the
evidence for deprescribing at an individual patient level.
Interventions that facilitate GPs access to, and dissemin-
ation of, the available evidence may facilitate deprescrib-
ing. For example, provision of evidence-based guidelines
with a structured dialogue may assist communicating
with residents and their families regarding deprescrib-
ing. Documentation of residents’ goals of care may
improve decision-making, and ensure the well-being of
the resident remains forefront in prescribing decisions.
Nurses may beneﬁt from interventions that improve the
communication with GPs, and also from educational
activities that address their understanding of residents’
medications and medical conditions. Interventions that
address pharmacists’ access to residents’ medical infor-
mation and improve communication between them-
selves and the family and other disciplines may improve
their ability to determine the resident’s goals of care.
Interventions that improve communication between resi-
dents and health professionals, including interventions
to improve continuity of nursing staff, may facilitate
deprescribing. Furthermore, interventions should con-
sider the priorities of residents and health professionals,
both individually and as a collective group.
Although this study was conducted in LTCFs, many
factors identiﬁed within this study may also be applicable
to deprescribing in older people in the broader commu-
nity setting. It was noted in the regional multidisciplinary
NGT that GPs who had long-established relationships
with residents found it challenging to discuss the transi-
tion from preventative to palliative care. This is likely to
be the same for GPs and community-dwelling patients
with long-established relationships. As with the LTCF
setting, maintaining the patient’s well-being at the centre
of prescribing decisions is likely to be an important
factor for community-dwelling older people.
Strengths and limitations
Our study included an independent experienced facilita-
tor and a well-deﬁned methodology to elicit a wide
range of factors important for deprescribing. Using
NGT minimised any pressure that participants may have
felt to conform.28 Furthermore, participants discussed
the ﬁnal rankings to ensure they were a true reﬂection
of the group. Bias was minimised through using identi-
cal background reading material for each group. While
this background was based on the current literature
relating to deprescribing, it was speciﬁcally written in lay
terms to account for residents unfamiliar with the
subject matter. Participants were recruited from a large
geographical area allowing for a range of opinions to be
captured. However, the results may not be generalisable
to other clinical settings and other countries. Collection
of the number of years since registration was a strength
of the study as it highlighted the diversity of experience
within the each group, however, details relating to spe-
ciﬁc geriatric training were not collected. It is therefore
uncertain if geriatric training impacts on factors consid-
ered important for deprescribing. Owing to recruitment
by invitation, the sample may be biased towards moti-
vated and enthusiastic participants. This was a strength
because it enabled a rich discussion of factors important
for deprescribing. However, it is unclear whether less
motivated participants perceive similar factors as import-
ant. Deprescribing is a complex process which involves
many steps.10 55 Despite qualitative research having lim-
itations,28 qualitatively describing the factors important
for the resident and health professionals may facilitate
the deprescribing.41 However, difference may exist
between the expressing of an opinion in a research
study and expressing an opinion in a clinical setting.
Further research is required to see which factor or
group of factors need to be addressed to improve depre-
scribing in clinical practice.
CONCLUSION
Using NGT, factors important for deprescribing in
LTCFs were identiﬁed and prioritised by each discipline-
speciﬁc group. Important factors identiﬁed include ‘evi-
dence for deprescribing’, ‘GP receptivity to deprescrib-
ing’, ‘clinical appropriateness of therapy’ and ‘wellbeing
of the resident’. The multidisciplinary groups’ priori-
tised both ‘adequacy of medical and medication history’
and ‘identifying residents’ goals of care’. Common and
contrasting factors were generated between groups, and
where similarities existed between groups, they were
prioritised differently. Future deprescribing interven-
tions need to recognise and address the similarities and
differences within the range of factors prioritised by resi-
dents and health professionals.
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